Summit Therapeutics (SMMT) added ~5% in the premarket on Thursday after the company announced that the U.S. FDA accepted its Biologics License Application (BLA) for its lead asset ivonescimab developed with its Chinese partner Akeso (AKESF). The BLA seeks the Post navigation Unicycive granted FDA review for resubmitted marketing application for kidney disease drugNanoMosaic Secures FDA Advanced Manufacturing Technology (AMT) Designation for Advanced Gene Therapy Analytics
